Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers.
SAKER ; ESCURET ; PITIOT ; MASSARDIER-PILONCHERY ; PAUL ; MOKDAD ; LANGLOIS-JACQUES ; RABILLOUD ; GONCALVES ; FABIEN ; GUIBERT ; FASSIER ; BAL ; TROUILLET-ASSANT ; TRABAUD
Type de document
ARTICLE A COMITE DE LECTURE REPERTORIE DANS BDI (ACL)
Langue
anglais
Auteur
SAKER ; ESCURET ; PITIOT ; MASSARDIER-PILONCHERY ; PAUL ; MOKDAD ; LANGLOIS-JACQUES ; RABILLOUD ; GONCALVES ; FABIEN ; GUIBERT ; FASSIER ; BAL ; TROUILLET-ASSANT ; TRABAUD
Résumé / Abstract
With the availability of vaccines, commercial assays detecting anti-SARS-CoV-2 antibodies (Ab) evolved towards quantitative assays directed to the spike glycoprotein or its receptor binding domain (RBD). The main objective of the present study was to compare the Ab titers obtained with quantitative commercial binding Ab assays, after 1 dose (convalescent individuals) or 2 doses (naïve individuals) of vaccine, in healthcare workers (HCW).
Source
Journal of Clinical Microbiology
Editeur
American Society for Microbiology
